

Emosis raises 1 million euros to launch a first test kit in the European market

**A year after its founding, Emosis raises 1 million euros Series A
from Cap Innov'Est, to launch in 2017, a first in vitro diagnostic kit
for use in the hemostasis field**

Strasbourg, France, March 2016 | [Emosis](#), a French company specializing in developing and marketing easy-to-use high performance hemostasis tests, announces the closing of a 1 million euro round of funding from Cap Innov'Est. This is the first capital invested since the founding of the company in January 2015.

The proceeds will be primarily used to market the first in a series of novel in vitro diagnostics test kits to diagnose and assess hemostasis disorders. This first kit, due for launch in 2017, will be used to confirm the diagnosis of Heparin-Induced Thrombocytopenia (HIT).

HIT is a rare, but life-threatening, disorder that is frequently suspected in hospital in-patients treated with heparin. (It is estimated that about 12 million hospitalized Americans receive some form of heparin each year, and up to 5% of these may develop HIT.) In HIT, heparin (an anticoagulant drug) paradoxically triggers severe clotting complications. Tests currently used for confirming HIT have to be performed by experienced operators in a restricted number of specialized laboratories.

This Emosis test will enable rapid, routine confirmation of HIT on site, i.e. in the medical biology laboratory of the hospital where the patient is receiving care, with significant medical and economic benefits.

* Cap Innov'Est is a closed private equity fund managed by [Alsace Capital](#) with the support of Invest PME.

QUOTES

Frédéric Allemand, MD, CEO, commented: *"We are very pleased to have Cap Innov'Est on board. They share our vision to grow Emosis into an international company with a leading franchise in hemostasis diagnostics, a segment with a promising growth perspective."*

Professor **Aaron Tomer**, MD, MSc, CSO, added: *"We are very happy that patients will soon start to benefit from Emosis tests. Our HIT test will be the first of our series of tests to enter medical laboratory and clinical practice, and we are confident that it will very quickly become the 'go-to' test to confirm suspected cases of HIT."*

Anh Nguyen, PhD, MBA, Chairman of the Supervisory Board, is proud of the progress made so far: *"This capital investment is the culmination of 4 years of intensive work that has taken Emosis to a level of product and managerial maturity rarely seen for such a young company."*

Jean-François Rax, Investor at Alsace Capital summed up: *"This investment gives Emosis the best possible start as they progress their plans to take their first product into the in vitro diagnostics market. A successful launch will validate the potential of Emosis kits and underline the company's capability to market this innovative new system."*

EMOSIS is an in vitro diagnostics company founded by a Franco-Israeli-American team. This team has developed a first-in-class, high-performance and user-friendly system that combines a series of kits and a dedicated device to diagnose, differentiate and quantify hemostasis disorders. The company was created in Montpellier in January 2015, having been incubated at the regional Languedoc-Roussillon Incubation site, and supported by the Business Innovation Center.

Emosis transferred its headquarters to Alsace in October 2015 while keeping a site in Languedoc-Roussillon in order to support locally forthcoming development of collaborative projects.

Emosis has received numerous awards from different bodies:

- 2013: the Concours Tremplin Entreprises - a start-up contest organized by the French Senate - achieved official recognition for innovation
- 2014: the Concours I-Lab - a start-up contest organized by the French Ministry of Higher Education and Research - awarded a grant of 250 000 euros
- 2014: NETVA (New Technology Venture Accelerator) - awarded access to a program of preparation and exposure to high-tech US markets for young innovative French companies, run by the Office for Science & Technology of the Embassy of France in the United States.

THE NEED FOR EMOSIS PRODUCTS

Current hemostasis tests typically monitor net anticoagulant activity, and provide incomplete insight into the mechanism underlying a hemostatic disorder. On the contrary, Emosis tests assess platelets behavior in minute detail and, in so-doing, provide a more informative, accurate, and quantitative complete picture of the underlying hemostasis abnormality: where there may be a problem, and the extent of that problem.

In addition, using minimal blood sampling, the tests can be performed in patient populations who, at present, have no access to current tests.

Furthermore, Emosis tests will be the first hemostasis tests to be performed on dedicated software-controlled benchtop flow cytometers - a widely-used technology known for its accuracy and precision. Unlike current tests, Emosis tests can be performed without specialized training, are accessible to any typically-equipped hospital laboratory and can be performed quickly and routinely at affordable costs similar to those of currently existing hemostasis tests.

ABOUT HEMOSTASIS DISORDERS

Hemostasis is the process by which blood is maintained in a fluid state within the circulatory system, and which forms a clot at the site of a vessel injury to stop blood loss.

Hemostasis disorders, either disease-related or drug-induced e.g., 5% of the French population is treated with antiplatelet agents). Those disorders are suspected when there is:

- a bleeding event such as purpura (cutaneous or mucosal bleeding), excessive menstruation, surgical bleeding, hemorrhagic stroke, etc.

or

- a clotting event such as: ischemic stroke, myocardial infarction, venous thrombosis, pulmonary embolism, thrombotic complication of cancer, recurrent miscarriage and other pregnancy-related vascular complications, etc.

Valued at more than \$1.5 billion worldwide*, the hemostasis market represents 3% of the in vitro diagnostics market. *Source: BioMarket Trends - Dec 1, 2012 (Vol. 32, N°21)

INVESTMENT PARTNERS

Cap Innov'Est is a €36 million French inter-regional funds (Alsace, Bourgogne, Franche-Comté) investing in young innovative start-ups. The funds, in operation since July 2014, have invested in 10 start-ups so far. Cap Innov'Est subscribers are Fonds National d'Amorçage, Regions of Alsace, Bourgogne and Franche-Comté, SAFIDI, caisses d'épargne d'Alsace et Bourgogne/Franche-Comté, BNP Paribas & CIFIC.

For more information: www.alsacecapital.eu

CONTACT

OXYGEN PR

Maiwenn REGNAULT - Tel. +1 (415) 609 0140 / maiwenn@oxygen-pr.com

Emosis - Frédéric Allemand, CEO, frederic.allemand@emosis-diagnostics.com

Cap Innov'est - Jean-François Rax, Director of Participations, jfrax@alsacecapital.eu

www.emosis-diagnostics.com
